Related Experiment Video
Updated: Apr 24, 2026

Author Spotlight: Enhancing Transplantation Research Through MicroCT Angiography in Murine Models
Published on: September 22, 2023
Hepatitis C genotype influences post-liver transplant outcomes
Isabel Campos-Varela1, Jennifer C Lai, Elizabeth C Verna
11 Division of Gastroenterology and Hepatology, University of California-San Francisco, San Francisco, CA. 2 Division of Gastroenterology and Hepatology, New York Presbyterian Hospital-Columbia, New York, NY. 3 Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX. 4 Section of Hepatology and Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA. 5 Division of Hepatology, University of Colorado, Denver, CO.
Hepatitis C virus (HCV) genotype significantly impacts liver transplant outcomes. Genotype 1 is associated with higher advanced fibrosis risk and lower treatment response, necessitating tailored management strategies.
Area of Science:
- Hepatology
- Transplant Immunology
- Virology
Background:
- Hepatitis C virus (HCV) genotype influences outcomes in non-transplant patients.
- The role of HCV genotypes in post-liver transplant disease progression requires further clarification.
Purpose of the Study:
- To investigate the impact of HCV genotypes on advanced fibrosis, graft loss, and antiviral therapy response in liver transplant recipients.
Main Methods:
- Analysis of the multicenter CRUSH-C cohort.
- Examined genotype-specific rates of advanced fibrosis, HCV-specific graft loss, and antiviral therapy response.
Main Results:
- HCV genotype 1 was linked to a higher risk of advanced fibrosis compared to genotypes 2 and 3.
- Genotype 2 and 3 showed significantly lower risks of advanced fibrosis and higher sustained virologic response rates to antiviral therapy.
- No significant difference in 5-year HCV-specific graft survival rates across genotypes.
Conclusions:
- HCV genotype is a critical determinant of advanced fibrosis risk and treatment response post-liver transplantation.
- Liver transplant recipients with HCV genotype 1 face the greatest risk of advanced fibrosis and have the poorest response to therapy.
- Genotype-specific management strategies are essential for optimizing outcomes in HCV-infected liver transplant recipients.
Related Concept Videos
Hepatitis
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

